Abstract Number: PB1055
Meeting: ISTH 2020 Congress
Background: Brazil has the fourth largest haemophilia population in the world. All the patients are followed in the haemophilia treatment centres, which provide them interdisciplinary consultations and replacement factor for free. Since the last decade, Brazilian guidelines have been written in accordance to international standard-of-care. The mortality among Brazilian haemophilia people is decreasing and the relative incidence of cardiovascular (CVD) deaths is increasing.
Aims: The aim of the current analysis of the HemoCardio Study was to describe the CVD risk score according to ASCVD tool and its treatment recommendations.
Methods: Men with haemophilia 40 years or older were included. Patients who had previous CVD event or a low-density lipid cholesterol 190 mg/dL or higher were excluded. Interviews, medical file reviews, and blood tests were performed. The ASCVD tool (www.cvriskcalculator.com) was used to estimate CVD risk, considering age, gender, race, total cholesterol, high-density lipid cholesterol (HDL), systolic and diastolic blood pressures, treatment for systemic arterial hypertension, diabetes and smoking status.
Results: Among the 28 included patients, the median [interquartile range; IQR] age was 51.5 [IQR;46.0-58.8] years. The majority had haemophilia A, 42.9% were severe, 53.6% were on prophylaxis and 7.1% were inhibitor positive in the last year. The frequencies of obesity, current smokers, hypertension, diabetes, hypertriglyceridaemia, hypercholesterolaemia, and hypoHDLaemia were 21.4%, 14.3%, 64.3%, 18.5%, 15.4%, 50.0%, and 21.4%, respectively. Median ASCVD score was 6.0 [IQR;2.6-13.5], with 46.4% patients having a moderate-to-high risk. Statin use was suggested for 50.0% of the patients. Blood pressure was poorly controlled in half of the patients.
Conclusions: In conclusion, almost half of the men with haemophilia had a moderate-to-high ASCVD risk score with strong recommendations to improve control of dyslipidaemia and blood pressure.
To cite this abstract in AMA style:Camelo R, Duarte BP, Moura MCB, Costa NCM, Costa IM, Roncal CGP, Vanderlei AM, Guimaraes TMR, Caram Deelder C, Gouw SC, Rezende SM, van der Bom JG. ASCVD Risk Score among Haemophilia Patients: Time to Formally Evaluate Cardiovascular Risk in People with Haemophilia [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/ascvd-risk-score-among-haemophilia-patients-time-to-formally-evaluate-cardiovascular-risk-in-people-with-haemophilia/. Accessed May 6, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/ascvd-risk-score-among-haemophilia-patients-time-to-formally-evaluate-cardiovascular-risk-in-people-with-haemophilia/